Cell Signaling Technology

Product Pathways - Wnt / Hedgehog / Notch

TCF4 Antibody #2566

Applications Reactivity MW (kDa) Source
W IP H (M) (C) 58, 79 Rabbit

Applications Key:  W=Western Blotting  IP=Immunoprecipitation
Reactivity Key:  H=Human  M=Mouse  C=Chicken
Species enclosed in parentheses are predicted to react based on 100% sequence homology. Species cross-reactivity is determined by Western blot.

Specificity / Sensitivity

TCF4 Antibody detects endogenous levels of total TCF4 protein. It is expected to recognize most, if not all, human TCF4 splicing isoforms.

Source / Purification

Polyclonal antibodies are produced by immunizing rabbits with a synthetic peptide (KLH-coupled) corresponding to residues surrounding Leu330 of human TCF4. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of whole cell lysates from DLD1 and HCT116 cells, using TCF4 antibody.

Background

LEF1 and TCF are members of the high mobility group (HMG) DNA binding protein family of transcription factors which consists of the following: Lymphoid enhancer factor 1 (LEF1), T Cell Factor 1 (TCF1), TCF3 and TCF4 (1). LEF1 and TCF1 were originally identified as important factors regulating early lymphoid development (2) that act downstream in Wnt signaling. LEF1/TCF bind to Wnt response elements to provide a docking site for β-catenin, which translocates to the nucleus to promote the transcription of target genes upon activation of Wnt signaling (3). LEF1/TCF proteins are dynamically expressed during development and aberrant activation of the Wnt signaling pathway is involved in many types of cancers including colon cancer (4,5).

TCF4, also known as TCF7L2, is expressed widely during development. Gene targeting study indicates that it is required to maintain the crypt stem cells of the small intestine (5, 6). TCF4 has many different splicing isoforms and they are expressed differentially in tissues and in cancers of different stages (8, 9). Studies also indicate that variant of the TCF4 gene confers an increased risk of type 2 diabetes (10).

  1. Waterman, M.L. (2004) Cancer Metastasis Rev. 23, 41-52.
  2. Schilham, M.W. and Clevers, H. (1998) Semin. Immunol. 10, 127-132.
  3. Brantjes, H. et al. (2002) Biol. Chem. 383, 255-261.
  4. Reya, T. and Clevers, H. (2005) Nature 434, 843-850.
  5. Logan, C.Y. and Nusse, R. (2004) Annu. Rev. Cell Dev. Biol. 20, 781-810.
  6. Cho, E.A. and Dressler, G.R. (1998) Mech Dev 77, 9-18.
  7. Korinek, V. et al. (1998) Nat Genet 19, 379-83.
  8. Howng, S.L. et al. (2004) Int J Oncol 25, 1685-92.
  9. Shiina, H. et al. (2003) Clin Cancer Res 9, 2121-32.
  10. Grant, S.F. et al. (2006) Nat Genet 38, 320-3.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

Product Pathways

Drug Discovery Tools

Featured Technologies

Protein Classes